The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 20 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 14 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: September Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 83% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 7 Number […]
On August 8, Spero Therapeutics, Inc. (SPRO) announced positive topline results from its Phase 3 clinical trial. The ADAPT-PO clinical trial evaluates Spero’s oral antibiotic candidate tebipenem HBr for the treatment of complicated urinary tract (cUTI) infection and acute pyelonephritis (AP) in adults. The results showed that Spero’s oral treatment was statistically non-inferior to intravenous […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 6% Other stats: Number of signals over $10/share 7 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: July Scorecard Number of Signals 14 Percent Correct – Prev Close to 5-day Peak 93% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 10 Number […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: June Scorecard Number of Signals 24 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 16% Other stats: Number of signals over $10/share 14 Number […]
Ekso Bionics Holdings, Inc. (EKSO) announced on June 25 that it received 501(k) clearance from the FDA to market its EksoNRTM robotic exoskeleton to patients with acquired brain injuries. The FDA previously cleared EksoNR for stroke and spinal cord injury rehabilitation in 2016, and it is the first such device cleared for use in patients with […]
On June 15, the FDA approved Eli Lilly and Company’s (LLE) new drug, Lyumjev™. It is a new rapid-acting form of insulin designed to speed the absorption of insulin into the blood stream and resduce A1C levels. Lyumjev is a novel formulation of insulin lispro that controls high blood sugar after meals in adults with […]
The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: May Scorecard Number of Signals 22 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 15 Number […]
On May 26, argenx (ARGX) reported positive Phase 3 clinical trial results from the ADAPT trial of efgartigimod. The ADAPT trial evaluates improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score for acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients. Respondents in the trial saw an improvement of at least two points […]
Simply register below to get sample signals as they come out!
